Insight, China's Pharmaceutical Industry

PolyMed Biopharmaceuticals Completes Pre‑A++ Funding Round Led by Caleb Capital, Fuels PROTAC‑Focused Pipeline

PolyMed Biopharmaceuticals Co., Ltd., a Chinese‑based, internationally‑oriented biopharma innovator, announced the successful closure of its...

Policy / Regulatory

NMPA Releases Draft Measures on Drug Quality Sampling, Seeks Public Comments by Nov 5

Fineline Cube Oct 28, 2025

The National Medical Products Administration (NMPA) today issued the “Measures for the Administration of Drug...

Policy / Regulatory

Novartis Asciminib Enters China’s SPARK Program for Pediatric Chronic Myeloid Leukemia

Fineline Cube Oct 28, 2025

The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) announced today...

Others

WuXi AppTec Sells WuXi Clinical and MedKey to Hillhouse for RMB 2.8 Billion

Fineline Cube Oct 28, 2025

WuXi AppTec (Shanghai) Co., Ltd., a wholly‑owned subsidiary of Wuxi AppTec Co., Ltd. (SHA: 603259,...

Company

Wuxi Apptec Reports 15.3 % YoY Revenue Growth in Q3 2025, Net Profit Hits RMB 4.22 Billion

Fineline Cube Oct 28, 2025

Wuxi Apptec Co., Ltd. (SHA: 603259, HKG: 2359) today announced third‑quarter 2025 financial results, delivering...

Company Drug

Grand Pharma Launches GPN00884 Clinical Trial to Tackle Pediatric Myopia Progression

Fineline Cube Oct 27, 2025

Grand Pharmaceutical Group Limited (HKG: 0512), a China-based company, announced on October 26, 2025, that...

Company Deals

Novartis Strikes USD 12b Deal for Avidity’s RNA Therapeutics and Gene-Targeted Pipeline

Fineline Cube Oct 27, 2025

Novartis (NYSE: NVS) announced an agreement to acquire San Diego-based biotech Avidity Biosciences for USD...

Company Deals

Eli Lilly to Acquire Adverum Biotechnologies for Up to USD 261.7m for Ixo-vec Access

Fineline Cube Oct 27, 2025

Eli Lilly (NYSE: LLY) announced on October 24, 2025, that it will acquire gene therapy...

Company Drug

Alphamab Oncology’s JSKN003 Approved for Phase III Trial in HER2-Positive CRC

Fineline Cube Oct 27, 2025

Alphamab Oncology (HKG: 9966), a China-based biotechnology company, announced on October 27, 2025, that its...

Company Deals

AstraZeneca Launches Sixth Global R&D Center in Beijing to Accelerate China Investments

Fineline Cube Oct 27, 2025

AstraZeneca (AZ, NASDAQ: AZN) announced on October 25, 2025, the launch of its sixth Global...

Company Drug

Chiesi Group Launches First EB Wound Treatment in China

Fineline Cube Oct 27, 2025

The Italian Chiesi Group announced on October 25, 2025, the successful launch of its innovative...

Company Deals

Chugai to Acquire Renalys Pharma for JPY 31 Billion to Expand IgA Nephropathy Treatment Portfolio

Fineline Cube Oct 27, 2025

Chugai Pharmaceutical, a member of the Roche Group, announced on October 24, 2025, that it...

Company Drug

Innovent’s Mazdutide Meets Phase III Endpoint in Type 2 Diabetes and Obesity Trial

Fineline Cube Oct 27, 2025

Innovent Biologics (HKG: 1801) announced on October 27, 2025, that its fourth Phase III clinical...

Company

Sunshine Guojian Reports Strong Q3 Growth and Advances Key R&D Programs

Fineline Cube Oct 27, 2025

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (SHA: 688336), a China-based company, released its 2025 third-quarter...

Company

Astellas Establishes First China Innovation R&D Center in Beijing BioPark

Fineline Cube Oct 27, 2025

Astellas Pharma (TYO: 4503) announced on October 27, 2025, the establishment of its first China...

Company Deals

Novartis Transfers Lucentis and Beovu Rights to CMS Vision in China Deal

Fineline Cube Oct 27, 2025

Novartis (NYSE: NVS) announced on October 27, 2025, the signing of a strategic cooperation agreement...

Company Deals

GSK Secures Global Rights to Syndivia’s ADC for Metastatic Prostate Cancer

Fineline Cube Oct 27, 2025

British pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) and Syndivia announced on October 27, 2025, that...

Company Drug

Zhifei’s CA111 Injection Approved for Clinical Trials Targeting Weight Loss and Hypoglycemia

Fineline Cube Oct 27, 2025

Chongqing Zhifei Biological Co., Ltd’s (SHE: 300122) subsidiary, Chongqing Chenan Biopharmaceutical Co., Ltd., has received...

Company Drug

LEO Pharma Submits NDA for Anzupgo in China for Chronic Hand Eczema

Fineline Cube Oct 27, 2025

LEO Pharma announced on October 17, 2025, that it has submitted a New Drug Application...

Company Deals

Eli Lilly Partners with Cipla to Distribute New Tirzepatide Brand “Yurpeak” in India

Fineline Cube Oct 25, 2025

Eli Lilly and Company (India) Pvt. Ltd. (Lilly) and Cipla Limited (BOM: 500087, NSE: CIPLA) today announced a...

Insight, China's Pharmaceutical Industry

GRIT Biotechnology and Drug Farm Sign Deep Collaboration Agreement to Co‑Create KunEvo, an AI‑Native Biotech R&D Platform for First‑in‑Class Drug Discovery

Hangzhou Eli Radiopharma and Shanghai Smartlogic Sign Strategic Cooperation Agreement to Advance Computation‑Driven Radiopharmaceutical Discovery and Co‑Build Cyclic Peptide Platform

Sun-Novo and GemPharmatech Sign Long‑Term Strategic Cooperation Agreement to Deepen Preclinical Collaboration on Small Nucleic Acid Therapeutics and Build Closed‑Loop AOC R&D System

Gan & Lee Pharmaceuticals Signs Out‑Licensing Deal With Menarini on Bonfaglutide, a Twice‑Monthly GLP‑1 RA, Worth Up to EUR 726 Million Across 39 European Markets

Jazz Pharmaceuticals to Acquire Actio Biosciences for Up to USD 1.32 Billion, Gaining First‑in‑Class KCNT1 Ion Channel Inhibitor ABS‑1230 for Ultra‑Rare Epilepsy

Zhifei Biological Submits Clinical Trial Application in China for Nasal Spray Recombinant RSV Vaccine Based on Chimpanzee Adenovirus Vector

Keymed Biosciences’ Bispecific Antibody CM512 Achieves All Endpoints in Phase 2 Trial for Chronic Rhinosinusitis With Nasal Polyps

PolyMed Biopharmaceuticals Completes Pre‑A++ Funding Round Led by Caleb Capital, Fuels PROTAC‑Focused Pipeline

NMPA Releases Draft Measures on Drug Quality Sampling, Seeks Public Comments by Nov 5

Novartis Asciminib Enters China’s SPARK Program for Pediatric Chronic Myeloid Leukemia

WuXi AppTec Sells WuXi Clinical and MedKey to Hillhouse for RMB 2.8 Billion

Wuxi Apptec Reports 15.3 % YoY Revenue Growth in Q3 2025, Net Profit Hits RMB 4.22 Billion

Grand Pharma Launches GPN00884 Clinical Trial to Tackle Pediatric Myopia Progression

Novartis Strikes USD 12b Deal for Avidity’s RNA Therapeutics and Gene-Targeted Pipeline

Eli Lilly to Acquire Adverum Biotechnologies for Up to USD 261.7m for Ixo-vec Access

Alphamab Oncology’s JSKN003 Approved for Phase III Trial in HER2-Positive CRC

AstraZeneca Launches Sixth Global R&D Center in Beijing to Accelerate China Investments

Chiesi Group Launches First EB Wound Treatment in China

Chugai to Acquire Renalys Pharma for JPY 31 Billion to Expand IgA Nephropathy Treatment Portfolio

Innovent’s Mazdutide Meets Phase III Endpoint in Type 2 Diabetes and Obesity Trial

Sunshine Guojian Reports Strong Q3 Growth and Advances Key R&D Programs

Astellas Establishes First China Innovation R&D Center in Beijing BioPark

Novartis Transfers Lucentis and Beovu Rights to CMS Vision in China Deal

GSK Secures Global Rights to Syndivia’s ADC for Metastatic Prostate Cancer

Zhifei’s CA111 Injection Approved for Clinical Trials Targeting Weight Loss and Hypoglycemia

LEO Pharma Submits NDA for Anzupgo in China for Chronic Hand Eczema

Eli Lilly Partners with Cipla to Distribute New Tirzepatide Brand “Yurpeak” in India

You Missed

GRIT Biotechnology and Drug Farm Sign Deep Collaboration Agreement to Co‑Create KunEvo, an AI‑Native Biotech R&D Platform for First‑in‑Class Drug Discovery

Hangzhou Eli Radiopharma and Shanghai Smartlogic Sign Strategic Cooperation Agreement to Advance Computation‑Driven Radiopharmaceutical Discovery and Co‑Build Cyclic Peptide Platform

Sun-Novo and GemPharmatech Sign Long‑Term Strategic Cooperation Agreement to Deepen Preclinical Collaboration on Small Nucleic Acid Therapeutics and Build Closed‑Loop AOC R&D System

Gan & Lee Pharmaceuticals Signs Out‑Licensing Deal With Menarini on Bonfaglutide, a Twice‑Monthly GLP‑1 RA, Worth Up to EUR 726 Million Across 39 European Markets